MRMaksym Rzhanyi

Maksym Rzhanyi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Maksym Rzhanyi has a total of 8 co-authors. Here are the top co-authors by number of shared publications:

  • Kostiantyn V. Rudenko

    State Institution “National Scientific Center of Cardiovascular Surgery and Hereditary Pathology named after M. M. Amosov of the National Academy of Medical Sciences of Ukraine”, Kyiv

    2 shared publications
  • Polina A. Danchenko

    Department of Myocardial Pathology, Heart Transplantation and Mechanical Circulatory Support, Amosov National Institute of Cardiovascular Surgery , Kyiv 03038

    2 shared publications
  • A. O. Bei

    National Scientific Center of Cardiovascular Surgery and Hereditary Pathology named after M. M. Amosov of the National Academy of Medical Sciences of Ukraine

    1 shared publication
  • Liliana Hrubiak

    Department of Surgical Treatment of Infective Endocarditis, Amosov National Institute of Cardiovascular Surgery, Kyiv, Ukraine

    1 shared publication
  • Mykhailo Kozhanov

    Department of Anesthesiology and Extracorporeal Circulation, Amosov National Institute of Cardiovascular Surgery, Kyiv, Ukraine

    1 shared publication
  • Mykhailo S. Ishchenko

    Radiology Department, Amosov National Institute of Cardiovascular Surgery, Kyiv, Ukraine

    1 shared publication

Latest Publications

  • Open Access

    Multidisciplinary management of patients with hypertrophic cardiomyopathy

    by K. V. Rudenko, P. A. Danchenko, M. I. Rzhanyi, O. O. Chyzhevska, A. O. Bei, O. M. Kovalyova

    The article presents a review of literary and scientific sources from the MEDLINE database on PubMed, Web of Science, Scopus, and Google Scholar platforms, focusing on hypertrophic cardiomyopathy and its treatment aspects. In accordance with the recommendations of leading experts, a modern definition of hypertrophic cardiomyopathy is shown with a description of the classification of structural and functional cardiac abnormalities, associated symptoms, and generalized risk factors for sudden cardiac death in patients. A ranking of patients related to the left ventricular outflow tract obstruction and clinical manifestations is submitted. Based on international guidelines, the main principles for treating patients are given, depending on hemodynamic and clinical characteristics, including pharmacotherapy and invasive methods. Pathophysiological reasoning and clinical justification for prescribing drugs to correct complications are provided. The use of septal myectomy and alcohol septal ablation to correct morphological cardiac abnormalities and improve the clinical status of patients is outlined in a historical context. The results of one’s own experience in surgical treatment of patients with hypertrophic cardiomyopathy are presented.


  • Contemporary surgical treatment of hypertrophic obstructive cardiomyopathy: insights from the Ukrainian National Referral Center

    by Polina Danchenko, Kostiantyn Rudenko, Maksym Rzhanyi, Liliana Hrubiak, Mykhailo Ishchenko, Mykhailo Kozhanov

    Purpose Hypertrophic obstructive cardiomyopathy (HOCM) remains a prevalent and clinically significant condition with a global prevalence of 1:200 to 1:500. In Ukraine, the estimated burden is approximately 75,000 patients, although national data remain limited. Since 2016, the Amosov National Institute of Cardiovascular Surgery in Kyiv has been a leading center for HOCM surgery, primarily performing septal myectomy (SM) with concomitant mitral valve (MV) repair. This review summarizes the evolution of the Institute’s surgical program, outcomes, and challenges faced under extraordinary circumstances. Methods Institutional experience with SM and MV repair between 2016 and 2025 was reviewed. Preoperative evaluation included transthoracic echocardiography (TTE), cardiac magnetic resonance (CMR) imaging, and/or computed tomography (CT). A refined transaortic SM technique was applied to optimize septal resection, relieve left ventricular outflow tract (LVOT) obstruction, and address dynamic mitral regurgitation (MR). Results SM consistently reduced LVOT gradients and eliminated MR in the majority of patients. In-hospital mortality remained below 1%, with a low incidence of major complications directly attributable to myectomy. Despite significant external pressures, including the coronavirus disease 2019 (COVID-19) pandemic and the ongoing full-scale war in Ukraine, surgical activity continued without interruption. Innovations in operative techniques and perioperative management further enhanced safety and outcomes. Conclusion The Amosov Institute has established a high-performing national program for HOCM surgery, demonstrating durable results despite unprecedented challenges. Ongoing refinement of minimally invasive strategies and strengthened international collaboration remain essential to address the global shortage of experienced myectomy surgeons and ensure wider access to advanced surgical care.